Services on Demand
- Cited by SciELO
- Access statistics
- Cited by Google
- Similars in SciELO
- Similars in Google
Anais Brasileiros de Dermatologia
Print version ISSN 0365-0596On-line version ISSN 1806-4841
FRAGA, Naiara Abreu de Azevedo et al. Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept. An. Bras. Dermatol. [online]. 2011, vol.86, n.4, suppl.1, pp.144-147. ISSN 0365-0596. http://dx.doi.org/10.1590/S0365-05962011000700038.
Psoriasis affects 0.12% to 0.71% of all children. Erythrodermic psoriasis is an uncommon but serious disorder, occurring in less than 1.5% of cases. Tumor necrosis factor-alpha blockers (TNF-α) are a new class of drugs used to treat moderate to severe psoriasis refractory to conventional therapies. Etanercept is a TNFα receptor fusion protein, approved by the FDA for treating juvenile rheumatoid arthritis. We present the case of a 7-year-old suffering from plaque psoriasis since 8 months old which evolved into erythroderma refractory to cyclosporine and methotrexate. Patient responded excellently to etanercept, with no adverse side effects
Keywords : Child; Psoriasis; Therapy.